Kisqali is a medication that has been approved by the FDA for the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It belongs to a class of drugs known as CDK4/6 inhibitors, which work by blocking certain proteins that promote the growth of cancer cells.

Clinical trials have shown that Kisqali, when used in combination with an aromatase inhibitor, can significantly improve progression-free survival in patients with advanced breast cancer. This means that the disease does not worsen as quickly as it would without treatment. Kisqali has also been shown to reduce the risk of the cancer spreading to other parts of the body.

As with any medication, there are potential side effects associated with Kisqali. These can include low white blood cell counts, nausea, fatigue, and liver problems. It is important for patients to discuss these potential side effects with their healthcare provider before starting treatment.

It is also important for patients to inform their healthcare provider about any other medications or supplements they are taking, as Kisqali may interact with certain drugs. Additionally, patients should follow their healthcare provider’s instructions carefully and attend all recommended follow-up appointments to monitor their response to treatment.

Overall, Kisqali has shown promise in improving outcomes for patients with advanced breast cancer. It is important for patients to have open and honest discussions with their healthcare provider about the potential benefits and risks of this medication in order to make informed decisions about their treatment plan.